Pyrrole derivatives as potential anti-cancer therapeutics: synthesis, mechanisms of action, safety / Halyna Kuznietsova, Natalia Dziubenko, Iryna Byelinska, Vasyl Hurmach, Andriy Bychko, Oksana Lynchak, Demyd Milokhov, Olga Khilya, Volodymyr Rybalchenko
Abstract Pyrrole derivatives (PDs) chloro-1-(4-chlorobenzyl)-4-((3-(trifluoromethyl)phenyl)amino)-1H-pyrrole-2,5-dione (MI-1) and 5-amino-4-(1,3-benzothyazol-2-yn)-1-(3-methoxyphenyl)-1,2-dihydro-3H-pyrrole-3-one (D1) were synthesised as inhibitors of several protein kinases including EGFR and VEGFR. The aim of the study was to reveal the exact mechanisms of PDs’ action EGFR and VEGFR are involved in. We observed, that both PDs could bind with EGFR and VEGFR and form stable complexes. PDs entered into electrostatic interactions with polar groups of phospholipid heads in cell membrane, and the power of interaction depended on the nature of PD radical substituents (greater for MI-1 and smaller for D1). Partial intercalation of MI-1 into the membrane hydrophobic zone also occurred. PDs concentrations induced apoptosis in malignant cells but normal ones had different sensitivity to those. MI-1 and D1 acted like antioxidants in inflamed colonic tissue, as evidenced by reduce of lipid and protein peroxidation products (by 43–67%) and increase of superoxide dismutase activity (by 40 and 58%) with restoring these values to control ones. MI-1 restored reduced haemoglobin and normalised elevated platelets and monocytes in settings of colorectal cancer, whereas D1 normalised only platelets. Thus, MI-1 and D1 could be used as competitive inhibitors of EGFR and VEGFR and antioxidants, which might contribute to realisation of their anti-inflammatory, proapoptotic and antitumor activity.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:28 |
|---|---|
| Enthalten in: |
Journal of drug targeting - 28(2020), 5, Seite 547-563 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kuznietsova, Halyna [VerfasserIn] |
|---|
| Links: |
FID Access [lizenzpflichtig] |
|---|
| Themen: |
Colon cancer |
|---|
| Umfang: |
1 Online-Ressource (17 p) |
|---|
| doi: |
10.1080/1061186X.2019.1703189 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
KFL011193921 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | KFL011193921 | ||
| 003 | DE-627 | ||
| 005 | 20230720210221.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230714s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/1061186X.2019.1703189 |2 doi | |
| 035 | |a (DE-627)KFL011193921 | ||
| 035 | |a (KFL)prod_LgpH_10.1080/1061186X.2019.1703189 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 084 | |a PHARM |q DE-84 |2 fid | ||
| 100 | 1 | |a Kuznietsova, Halyna |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Pyrrole derivatives as potential anti-cancer therapeutics: synthesis, mechanisms of action, safety |c Halyna Kuznietsova, Natalia Dziubenko, Iryna Byelinska, Vasyl Hurmach, Andriy Bychko, Oksana Lynchak, Demyd Milokhov, Olga Khilya, Volodymyr Rybalchenko |
| 264 | 1 | |c 2020 | |
| 300 | |a 1 Online-Ressource (17 p) | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Abstract Pyrrole derivatives (PDs) chloro-1-(4-chlorobenzyl)-4-((3-(trifluoromethyl)phenyl)amino)-1H-pyrrole-2,5-dione (MI-1) and 5-amino-4-(1,3-benzothyazol-2-yn)-1-(3-methoxyphenyl)-1,2-dihydro-3H-pyrrole-3-one (D1) were synthesised as inhibitors of several protein kinases including EGFR and VEGFR. The aim of the study was to reveal the exact mechanisms of PDs’ action EGFR and VEGFR are involved in. We observed, that both PDs could bind with EGFR and VEGFR and form stable complexes. PDs entered into electrostatic interactions with polar groups of phospholipid heads in cell membrane, and the power of interaction depended on the nature of PD radical substituents (greater for MI-1 and smaller for D1). Partial intercalation of MI-1 into the membrane hydrophobic zone also occurred. PDs concentrations induced apoptosis in malignant cells but normal ones had different sensitivity to those. MI-1 and D1 acted like antioxidants in inflamed colonic tissue, as evidenced by reduce of lipid and protein peroxidation products (by 43–67%) and increase of superoxide dismutase activity (by 40 and 58%) with restoring these values to control ones. MI-1 restored reduced haemoglobin and normalised elevated platelets and monocytes in settings of colorectal cancer, whereas D1 normalised only platelets. Thus, MI-1 and D1 could be used as competitive inhibitors of EGFR and VEGFR and antioxidants, which might contribute to realisation of their anti-inflammatory, proapoptotic and antitumor activity | ||
| 653 | |a Pyrrole derivatives | ||
| 653 | |a EGFR | ||
| 653 | |a VEGFR | ||
| 653 | |a lipid membranes | ||
| 653 | |a colonic inflammation | ||
| 653 | |a colon cancer | ||
| 653 | |a redox state | ||
| 653 | |a haematopoiesis | ||
| 700 | 1 | |a Dziubenko, Natalia |e verfasserin |4 aut | |
| 700 | 1 | |a Byelinska, Iryna |e verfasserin |4 aut | |
| 700 | 1 | |a Hurmach, Vasyl |e verfasserin |4 aut | |
| 700 | 1 | |a Bychko, Andriy |e verfasserin |4 aut | |
| 700 | 1 | |a Lynchak, Oksana |e verfasserin |4 aut | |
| 700 | 1 | |a Milokhov, Demyd |e verfasserin |4 aut | |
| 700 | 1 | |a Khilya, Olga |e verfasserin |4 aut | |
| 700 | 1 | |a Rybalchenko, Volodymyr |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of drug targeting |d Abingdon : Taylor & Francis Group, 1993 |g 28(2020), 5, Seite 547-563 |h Online-Ressource |w (DE-627)KFL000006076 |w (DE-600)2041932-6 |w (DE-576)273880632 |x 1029-2330 |7 nnns |
| 773 | 1 | 8 | |g volume:28 |g year:2020 |g number:5 |g pages:547-563 |
| 856 | 4 | 0 | |u http://pharmazie.proxy.fid-lizenzen.de/fid/tandf-ejournals-pharmazie/doi.org/10.1080/1061186X.2019.1703189 |m X:KFL |x Resolving-System |y FID Access |z lizenzpflichtig |
| 912 | |a ZDB-1-TFE | ||
| 912 | |a GBV_KFL | ||
| 912 | |a FID-PHARM | ||
| 935 | |i IMPORT_0628_prod_LgpH_02 | ||
| 951 | |a AR | ||
| 952 | |d 28 |j 2020 |e 5 |h 547-563 | ||